Population Impact Model of Faricimab and Aflibercept 8mg among US patients with Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration
Author(s)
Stella Ko, PharmD, Nicole Bonine, PhD, Fadoua El Moustaid, PhD;
Genentech, Inc, South San Francisco, CA, USA
Genentech, Inc, South San Francisco, CA, USA
Presentation Documents
OBJECTIVES: Anti-vascular endothelial growth factor (anti-VEGF) therapies are standard treatments for Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME). This study investigates the differences in direct/indirect costs associated with faricimab (anti-VEGF/Ang2) and aflibercept 8mg (anti-VEGF) treatments for nAMD and DME populations in the US, incorporating state-specific prevalence rates to identify cost savings.
METHODS: A cost analysis compared direct costs (drug, administration, and adverse event management) and indirect costs (travel costs and productivity loss) for patients treated with faricimab versus aflibercept 8mg and caregivers over 3 years. Injection frequency was derived from phase III clinical trials and extrapolated to 3 years. The Adelphi nAMD Real World Disease Specific Programme provided travel data, estimating an average travel distance of 12.33 miles and travel time of 32.54 minutes by car. Productivity loss from travel time was calculated with wage ($35.5/hour) applied to the caregiver unemployment rates (DME 50%, nAMD 76.9%). Results are reported per 100,000 population.
RESULTS: Faricimab per-patient direct costs were $2,221 and $10,385 lower than aflibercept 8mg after 3 years for DME and nAMD respectively. By incorporating the prevalence across the US, faricimab showed direct cost savings of $34.3M in DME and $431.2M in nAMD versus aflibercept 8mg. Combining both indications, faricimab resulted in direct cost savings of $466M and overall cost savings of $467M across the US. State-specific cost savings ranged from $5.08M to $13.5M for direct costs and from $5.07M to $13.6M for overall costs, leading to average cost savings of $9.13M and $9.15M respectively per state compared to aflibercept 8mg.
CONCLUSIONS: Compared to aflibercept 8mg, faricimab generated significant cost savings driven by injection frequency and lower drug costs, demonstrating its economic advantage considering varying prevalence rates by state.
METHODS: A cost analysis compared direct costs (drug, administration, and adverse event management) and indirect costs (travel costs and productivity loss) for patients treated with faricimab versus aflibercept 8mg and caregivers over 3 years. Injection frequency was derived from phase III clinical trials and extrapolated to 3 years. The Adelphi nAMD Real World Disease Specific Programme provided travel data, estimating an average travel distance of 12.33 miles and travel time of 32.54 minutes by car. Productivity loss from travel time was calculated with wage ($35.5/hour) applied to the caregiver unemployment rates (DME 50%, nAMD 76.9%). Results are reported per 100,000 population.
RESULTS: Faricimab per-patient direct costs were $2,221 and $10,385 lower than aflibercept 8mg after 3 years for DME and nAMD respectively. By incorporating the prevalence across the US, faricimab showed direct cost savings of $34.3M in DME and $431.2M in nAMD versus aflibercept 8mg. Combining both indications, faricimab resulted in direct cost savings of $466M and overall cost savings of $467M across the US. State-specific cost savings ranged from $5.08M to $13.5M for direct costs and from $5.07M to $13.6M for overall costs, leading to average cost savings of $9.13M and $9.15M respectively per state compared to aflibercept 8mg.
CONCLUSIONS: Compared to aflibercept 8mg, faricimab generated significant cost savings driven by injection frequency and lower drug costs, demonstrating its economic advantage considering varying prevalence rates by state.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
EE307
Topic
Economic Evaluation
Topic Subcategory
Work & Home Productivity - Indirect Costs
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, SDC: Sensory System Disorders (Ear, Eye, Dental, Skin)